Indicators of loco-regional recurrence in breast cancer

被引:22
作者
Sundquist, M
Thorstenson, S
Klintenberg, C
Brudin, L
Nordenskjöld, B
机构
[1] Cty Hosp, Dept Surg, S-39185 Kalmar, Sweden
[2] Cty Hosp, Dept Cytol & Pathol, S-39185 Kalmar, Sweden
[3] Cty Hosp, Dept Physiol, S-39185 Kalmar, Sweden
[4] Linkoping Univ Hosp, Dept Oncol, S-58185 Linkoping, Sweden
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 2000年 / 26卷 / 04期
关键词
breast cancer; recurrence; lymphovascular invasion; Nottingham histological grade;
D O I
10.1053/ejso.1999.0898
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: The aim of the investigation was to contribute to the identification of patients who have increased or decreased risk of loco-regional recurrence. Methods: Six hundred and twenty-nine consecutive patients with primary breast cancer diagnosed between 1988 and 1990 were studied. Two-thirds of the patients underwent mastectomy. Radiotherapy was administered if patients were node positive or breast conserved. The Nottingham histological grading protocol was used and presence of lymphovascular invasion was assessed. Investigated parameters were: age, size, grade, steroid receptor content, surgical radicality, vascular invasion and nodal status. Statistically significant risk factors for loco-regional recurrence using univariate or Cox proportional hazard analysis were grade and lymphovascular invasion. Results: Women with grade 1-2, node-negative tumours without vascular invasion had a very low loco-regional recurrence rate-3.1%. Seventeen percent of patients with grade 3 tumours and vessel invasion had loco-regional recurrence. Conclusions: Our findings, and those of others, indicate that the use of adjuvant radiotherapy should be influenced to a greater extent by grade and lymphovascular invasion. (C) 2000 Harcourt Publishers Ltd.
引用
收藏
页码:357 / 362
页数:6
相关论文
共 37 条
[1]  
ABE O, 1995, NEW ENGL J MED, V333, P1444
[2]   ADEQUATE LOCOREGIONAL TREATMENT FOR EARLY BREAST-CANCER MAY PREVENT SECONDARY DISSEMINATION [J].
ARRIAGADA, R ;
RUTQVIST, LE ;
MATTSSON, A ;
KRAMAR, A ;
ROTSTEIN, S .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (12) :2869-2878
[3]   RISK-FACTORS IN BREAST-CONSERVATION THERAPY [J].
BORGER, J ;
KEMPERMAN, H ;
HART, A ;
PETERSE, H ;
VANDONGEN, J ;
BARTELINK, H .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) :653-660
[4]   CAUSE-SPECIFIC MORTALITY IN LONG-TERM SURVIVORS OF BREAST-CANCER WHO PARTICIPATED IN TRIALS OF RADIOTHERAPY [J].
CUZICK, J ;
STEWART, H ;
RUTQVIST, L ;
HOUGHTON, J ;
EDWARDS, R ;
REDMOND, C ;
PETO, R ;
BAUM, M ;
FISHER, B ;
HOST, H ;
LYTHGOE, J ;
RIBEIRO, G ;
SCHEURLEN, H .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (03) :447-453
[5]   Breast conserving surgery for invasive breast cancer: Risk factors for ipsilateral breast tumor recurrences [J].
Dalberg, K ;
Mattsson, A ;
Rutqvist, LE ;
Johansson, U ;
Riddez, L ;
Sandelin, K .
BREAST CANCER RESEARCH AND TREATMENT, 1997, 43 (01) :73-86
[6]  
ELSTON CW, 1987, DIAGNOSTIC HISTOPATH, P300
[7]   8-YEAR RESULTS OF A RANDOMIZED CLINICAL-TRIAL COMPARING TOTAL MASTECTOMY AND LUMPECTOMY WITH OR WITHOUT IRRADIATION IN THE TREATMENT OF BREAST-CANCER [J].
FISHER, B ;
REDMOND, C ;
POISSON, R ;
MARGOLESE, R ;
WOLMARK, N ;
WICKERHAM, L ;
FISHER, E ;
DEUTSCH, M ;
CAPLAN, R ;
PILCH, Y ;
GLASS, A ;
SHIBATA, H ;
LERNER, H ;
TERZ, J ;
SIDOROVICH, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (13) :822-828
[8]   MORBIDITY OF ISCHEMIC-HEART-DISEASE IN EARLY BREAST-CANCER 15-20 YEARS AFTER ADJUVANT RADIOTHERAPY [J].
GYENES, G ;
FORNANDER, T ;
CARLENS, P ;
RUTQVIST, LE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 28 (05) :1235-1241
[9]   Radiotherapy for prevention of disease progression in early-stage Dupuytren's contracture: Initial and long-term results [J].
Keilholz, L ;
Seegenschmiedt, MH ;
Sauer, R .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 36 (04) :891-897
[10]   Evaluation of irradiated heart volumes in stage I breast cancer patients treated with postoperative adjuvant radiotherapy [J].
Gyenes, G ;
Gagliardi, G ;
Lax, I ;
Fornander, T ;
Rutqvist, LE .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) :1348-1353